Your browser doesn't support javascript.
loading
Correction to: A Phase II Study Evaluating Combined Neoadjuvant Cetuximab and Chemotherapy Followed by Chemoradiotherapy and Concomitant Cetuximab in Locoregional Oesophageal Cancer Patients.
Alsina, Maria; Rivera, Fernando; Ramos, Francisco Javier; Galán, Maica; López, Rafael; García-Alfonso, Pilar; Alés-Martinez, José Enrique; Queralt, Bernardo; Antón, Antonio; Carrato, Alfredo; Grávalos, Cristina; Méndez-Vidal, Maria José; López, Carlos; de Mena, Inmaculada Ruiz; Tabernero, Josep; Giralt, Jordi; Aranda, Enrique.
Afiliação
  • Alsina M; Vall d'Hebron University Hospital, Department of Medical Oncology, and Vall d'Hebron Institute of Oncology (VHIO), Universitat Autònoma de Barcelona, Passeig de la Vall d'Hebron, 119-129, Barcelona, Spain. malsina@vhio.net.
  • Rivera F; Department of Medical Oncology, H.U. Marqués Valdecilla, Av. Valdecilla, 25 Santander, Spain.
  • Ramos FJ; Vall d'Hebron University Hospital, Department of Medical Oncology, and Vall d'Hebron Institute of Oncology (VHIO), Universitat Autònoma de Barcelona, Passeig de la Vall d'Hebron, 119-129, Barcelona, Spain.
  • Galán M; Department of Medical Oncology, ICO Hospitalet, Avinguda de la Granvia, 199-203, Barcelona, Spain.
  • López R; Medical Oncology Department and Translational Medical Oncology Group, University Clinical Hospital and Health Research Institute (IDIS); CIBERONC, Santiago de Compostela University School of Medicine, Santiago de Compostela, Spain.
  • García-Alfonso P; Department of Medical Oncology, H. Gregorio Marañón, Calle del Dr. Esquerdo, 46, Madrid, Spain.
  • Alés-Martinez JE; Department of Medical Oncology, H. Ruber Internacional, Calle de la Masó, 38, Madrid, Spain.
  • Queralt B; Spain and H Nuestra Sra Sonsoles, C/ Avda. Juan Carlos I, Avila, Spain.
  • Antón A; Department of Medical Oncology, H. JosepTrueta (ICO), Avinguda de França, Girona, Spain.
  • Carrato A; Department of Medical Oncology, H. Miguel Servet, Paseo Isabel la Católica, 1-3, Zaragoza, Spain.
  • Grávalos C; Department of Medical Oncology, H. Ramón y Cajal, Ctra. Colmenar Viejo, km. 9, 100 Madrid, Spain.
  • Méndez-Vidal MJ; Department of Medical Oncology, H. 12 de Octubre, Avenida de Córdoba, Madrid, Spain.
  • López C; Maimonides Institute of Biomedical Research (IMIBIC), Reina Sofía Hospital, Department of Medical Oncology, University of Córdoba, CIBERONC, Instituto de Salud Carlos III, Av. Menendez Pida, Cordoba, Spain.
  • de Mena IR; Department of Medical Oncology, H.U. Marqués Valdecilla, Av. Valdecilla, 25 Santander, Spain.
  • Tabernero J; TTD Group, Madrid, Spain.
  • Giralt J; Vall d'Hebron University Hospital, Department of Medical Oncology, and Vall d'Hebron Institute of Oncology (VHIO), Universitat Autònoma de Barcelona, Passeig de la Vall d'Hebron, 119-129, Barcelona, Spain.
  • Aranda E; Department of Radiation Oncology, Vall d'Hebron University Hospital, Passeig de la Vall d'Hebron, 119-129, Barcelona, Spain.
Target Oncol ; 13(1): 79, 2018 02.
Article em En | MEDLINE | ID: mdl-29243205
ABSTRACT
Errors were subsequently identified in the article and the following corrections should be noted.
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2018 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2018 Tipo de documento: Article